

### Company Overview

CollPlant is a regenerative medicine company focused on 3D bioprinting of tissues and organs, and on developing and commercializing tissue repair products for orthobiologics, and advanced wound care markets. Our products are based on our rhCollagen (recombinant human collagen) that is produced with CollPlant's proprietary plant based genetic engineering technology.

Our products address indications for diverse fields of organ and tissue repair, and are ushering in a new era in regenerative medicine. Our flagship rhCollagen Biolnk product line is ideal for 3D bioprinting of tissues and organs, and our unique VergeNix line of rhCollagen products includes a soft tissue repair matrix for treating tendinopathy and a wound repair matrix to promote a rapid optimal healing of acute and chronic wounds.

### CollPlant Announces Appointment of Jonathan M.N. Rigby as Chairman of the Board

Feb 4 2019, 6:00 AM EST

### Stock Overview

<b>Symbol</b>	CLGN
<b>Exchange</b>	Nasdaq
<b>Market Cap</b>	19.05m
<b>Last Price</b>	\$5.00
<b>52-Week</b>	\$3.13 - \$8.73

02/15/2019 03:59 PM EST

### Investor Relations

Eran Rotem  
 Deputy CEO & CFO  
 T: +972 (73) 2325612  
 F: +972 (73) 2325602  
[eran@collplant.com](mailto:eran@collplant.com)

Corporate Profile®  
 Laurel Moody  
 1185 Avenue of the Americas 3rd  
 Floor  
 New York, NY 10036  
 T: +1 212 931 8787 Ext 101

Cybele Holdings Ltd.  
 Yael Schnitzer  
 T: +972(3)5755123  
[yael@cybele.co.il](mailto:yael@cybele.co.il)

### Management Team

#### Yehiel Tal

Chief Executive Officer

#### Prof. Oded Shoseyov

Founder, Chief Scientific Officer

#### Eran Rotem, CPA

Deputy CEO and Chief Financial Officer

#### Dr. Nadav Orr

Vice President, Research and Development

#### Dr. Ilana Belzer

Chief Operating Officer

#### Dr. Philippe Bensimon

Vice President, Regulatory Affairs and Quality Assurance

### CollPlant Holdings Ltd.

3 Sapir Street  
 Weizmann Science Park  
 Ness Ziona 74140  
 Israel

### Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.